SUMMARY Serum CA 19-9Tm antigen concentrations were measured in 246 patients with benign and histologically confirmed malignant gastrointestinal diseases. The CA 19-9 concentration was above the upper limit of the normal range (0-37 U/ml) in 76% of patients with pancreatic carcinoma, 73% of patients with cholangiocarcinoma, 42% of patients with gastric carcinoma, and 22% of patients with hepatoma. High CA 19-9 concentrations were found mainly in patients with a metastasised cancer, whereas 71% of patients with a localised carcinoma had normal CA 19-9 concentrations. All of the patients with benign gastric diseases had normal CA 19-9 values. Moderately increased concentrations were found in 15-36% of the patients with benign pancreatic, liver, and biliary tract diseases. a-fetoprotein was a better marker for hepatomas than CA 19-9. CA 19-9 was better than carcinoembryonic antigen in differentiating malignant from benign diseases. The results indicate that the CA 19-9 assay is not completely specific for cancer but serves as a valuable adjunct, especially in the diagnosis of pancreatic carcinoma.
CA 199TM radioimmunoassay is a new solid phase assay for the measurement of a diagnostic tumour marker defined by a monoclonal antibody. ' 2 This antibody was originally raised against a human cell line, SW 1116, which was derived from a colorectal carcinoma. ' The CA 19-9 antigen has been isolated and characterised as sialylated lacto-Nfucopentaose II, an oligosaccharide which is related to Lewisa blood group substance.4 5 Low concentrations of the CA 19-9 antigen are found in the serum of healthy subjects, but serum from patients with gastrointestinal adenocarcinoma, especially those of the pancreas, often contain increased concentrations of CA 19-9. ' The new test is reported to have a high specificity (98.5%) and a high sensitivity (up to 79%) for patients with gastrointestinal adenocarcinoma. ' We have determined the serum CA 19-9 concentration in 246 patients with benign and malignant diseases of the stomach, liver, pancreas, and biliary tract. We have also compared the new antigen with a-fetoprotein, a well established marker for liver cancer,6 and with carcinoembryonic antigen, which No correlation between the CA 19-9 and carcinoembryonic antigen concentrations was found (Fig. 2a) . The carcinoembryonic antigen concentration was increased in 17% of the patients with benign diseases and in 39% of the patients with cancer (Table) . Both markers were normal in 46% of the patients with cancer. An increased CA 19-9 value with a normal carcinoembryonic antigen concentration was found in 15% of the sera from patients with cancer, while the opposite was true in another 15%.
PANCREATIC DISEASE
Patients with benign pancreatic diseases had slightly higher CA 19-9 concentrations than patients with gastric diseases, but no value exceeded 100 U/ml (Fig. 1 ). Seventeen patients with cancer (68%) had values above 100 U/ml and 16 had values of 1000 U/ml or more. A normal CA 19-9 concentration was found in four of the six patients with localised carcinomas (Fig. 2) (Fig. 2b) .
LIVER DISEASES
An increased serum CA 19-9 concentration was found in 15% of the patients with benign liver diseases and in 22% of the patients with hepatomas ( Fig. 1) . No difference in the median values between these groups was found. Serum a-fetoprotein concentration was increased above 25 ug/l in 16 of the 18 patients with cancer. No correlation between the CA 19-9 and a-fetoprotein concentrations was found (Fig. 2c) .
BILIARY TRACT DISEASES
Pathological CA 19-9 concentrations were found in eight of the 11 patients with cholangiocarcinoma and in 35% of the patients with benign biliary tract diseases (range 5-3-440 U/ml). Liver metastases were found in 10 of the 11 patients with cancer. All of the patients with choledocholithiasis and increased CA 19-9 concentrations had obstructive jaundice.
Serum a-fetoprotein was slightly increased in one of the patients with cancer (56 ug/l); the other patients had normal values (Table) . Raised car- cinoembryonic antigen values were found in both benign and malignant biliary tract disease and in liver disease (Fig. 2b, Measurement of serum a-fetoprotein is a well established test in the diagnosis of liver cancer, and our results suggest that a-fetoprotein is a more sensitive and more specific marker for hepatoma than CA 19-9. Increased a-fetoprotein concentrations are found in 80% of patients with liver cell cancer and substantially increased values are rarely found in patients with benign liver disease or other gastrointestinal malignancies.6 The CA 19-9 concentration, on the other hand, was higher than 37 U/ml in 15% of the patients with benign liver disease and in only 22% of the patients with hepatoma. Two patients with cancer had normal a-fetoprotein concentrations and both also had normal CA 19-9 values. Thus it seems unlikely that the CA 19-9 antigen would be a reliable marker in patients with hepatoma with normal a-fetoprotein concentrations. .. Jalanko, Kuusela, Roberts, Sipponen, Haglund, 
